Skip to main content
HIGH TECH PHARM CO.,LTD. logo

HIGH TECH PHARM CO.,LTD. — Investor Relations & Filings

Ticker · 106190 ISIN · KR7106190002 KO Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2023-03-16 Audit Report / Informat…
Country KR South Korea
Listing KO 106190

About HIGH TECH PHARM CO.,LTD.

http://www.htpharm.com/eng/

HIGH TECH PHARM CO.,LTD. is a pharmaceutical company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs), with a primary focus on sterile, carbapenem-based antibiotic raw materials. Established in 1998, the company has gained global recognition for its advanced technology and high-quality products, which are supplied to over 40 countries. A significant majority of its sales are generated from exports to demanding overseas markets, including Europe. The company operates state-of-the-art manufacturing facilities, such as its Chungju plant, designed to meet the rigorous standards of advanced regulatory authorities like the U.S. FDA and European EDQM. Through a commitment to a quality-first policy and continuous research and development, HIGH TECH PHARM aims to solidify its position as a leading global supplier of antibiotic drug substances.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and confirmation of the audit report receipt date. While it contains financial data, it is a short, standardized regulatory announcement regarding the filing of the audit report rather than the full audit report document itself. Therefore, it fits the definition of a Regulatory Filing (RNS) as it is a formal announcement of a report submission. FY 2022
2023-03-16 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 25th fiscal year (2022) of Hi-Tech Pharm Co., Ltd. It contains comprehensive financial statements, management discussion and analysis, business overview, and corporate governance details. This is the standard Korean regulatory filing equivalent to an Annual Report (10-K). FY 2022
2023-03-16 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for the 25th Annual General Meeting of HT Pharm. It contains the meeting agenda, details on director appointments, financial statements, and voting procedures. In the context of corporate filings, documents that provide the agenda and materials for an upcoming Annual General Meeting are classified as AGM Information.
2023-03-09 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to provide shareholders with information regarding upcoming general meetings, including agenda items like financial statement approval, director appointments, and remuneration limits. This document is a formal proxy solicitation statement sent to shareholders to request their votes, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2023-03-09 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company 'Hitech Pharm'. It outlines the date, location, and specific agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes, which aligns with the Proxy Solicitation & Information Statement (PSI) category.
2023-02-28 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date'. It explains the company's inability to avoid the peak date due to operational constraints and outlines their commitment to shareholder participation. As this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves (AGM-R) or a proxy statement (PSI), it falls under the general regulatory filing category.
2023-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.